| 1 | Representative Schenck offered the following: |
| 2 |
|
| 3 | Amendment |
| 4 | Remove lines 1651-1667 and insert: |
| 5 | chapter 458, chapter 459, chapter 459, chapter 461, or chapter |
| 6 | 466 and pharmacies that would purchase or otherwise receive from |
| 7 | the wholesale distributor controlled substances listed in |
| 8 | Schedule II or Schedule III as provided in s. 893.03. The |
| 9 | wholesale distributor shall maintain records of such |
| 10 | credentialing and make the records available to the department |
| 11 | upon request. Such credentialing must, at a minimum, include: |
| 12 | 1. A determination of the clinical nature of the receiving |
| 13 | entity, including any specialty practice area. |
| 14 | 2. A review of the receiving entity's history of Schedule |
| 15 | II and Schedule III controlled substance purchasing from the |
| 16 | wholesale distributor. |
| 17 | 3. A determination that the receiving entity's Schedule II |
| 18 | and Schedule III controlled substance purchasing history, if |
| 19 | any, is consistent with and reasonable for that entity's |
| 20 | clinical business needs. |
| 21 | 4. Conduct of a level 2 background screening |